logo
Plus   Neg
Share
Email
Comment

Novartis: Omalizumab Met All Goals In Phase III Safety Registration Study In CSU

Swiss drugmaker Novartis AG (NVS) Wednesday announced late-breaking results showing
omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria or CSU, a chronic and debilitating form of hives with limited approved treatment options.

GLACIAL is the second of three pivotal Phase III studies that examine the efficacy and safety of omalizumab in CSU.

The study results supported the efficacy, safety and tolerability of omalizumab in patients with refractory CSU, a chronic and debilitating skin disease with intractable itch and hives.

Up to 40 percent of CSU patients fail on antihistamines, even those taking up to four times the approved dose. Antihistamines, at the approved dose, are currently the only licensed treatment for CSU.

Omalizumab is not currently approved or indicated for CSU. Regulatory submissions for omalizumab in CSU are on track for later this year, Novartis noted. It is being jointly developed by Novartis and Genentech, Inc.

The data was presented for the first time at the European Academy of Allergy and Clinical Immunology-World Allergy Organization World Allergy and Asthma Congress 2013 in Milan, Italy.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BlackBerry Ltd. has introduced a new a cloud-based cybersecurity program that will scan automakers' software for threats amid increased concerns about hacking in Internet-connected cars. BlackBerry Jarvis, the transformational software cybersecurity product, helps carmakers detect security flaws in software before it goes into their vehicles. General Motors Co. said it plans to mass-produce self driving cars that will have no steering wheel, pedals or manual controls by 2019. The automaker has filed a safety petition with the Department of Transportation for its fourth-generation self-driving Cruise AV, its first production-ready vehicle built from the start to operate safely on its own. Wells Fargo & Co. on Friday reported an 18 percent increase in profit for the fourth quarter from last year, reflecting a net benefit from the recent U.S. tax reform and a gain on sale of Wells Fargo Insurance Services, in addition to higher revenues. Earnings per share for the quarter beat analysts' expectations, while revenues missed their estimates.
comments powered by Disqus
Follow RTT